Loading
Low-Dose Aspirin / Breast Carcinoma / Questionnaire Administration · Phase 2 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration for a planned study of low-dose aspirin in postpartum women, targeting inflammatory markers as a potential mechanism to reduce postpartum-related breast cancer risk. No results have been posted in this registry record; the study is actively recruiting. The work remains mechanistic and surrogate-endpoint driven, intended to inform larger efficacy studies rather than guide clinical practice.
Phase 2, Interventional, Single Group, Open label, Prevention purpose. Breast Carcinoma; Female; age from 18 Years; to 45 Years; accepts healthy volunteers. Intervention: Prevention (low-dose aspirin). n = 60. 5 sites: United States.
This is a Phase 2 trial registration for a planned study of low-dose aspirin in postpartum women, targeting inflammatory markers as a potential mechanism to reduce postpartum-related breast cancer risk. No results have been posted in this registry record; the study is actively recruiting. The work remains mechanistic and surrogate-endpoint driven, intended to inform larger efficacy studies rather than guide clinical practice.
No information provided on blinding, randomization method, or safety monitoring plan.
No clinical impact can be inferred from this registration record alone. Results will be needed to determine whether aspirin-induced inflammation reduction correlates with cancer risk reduction in this population.
Phase 2 interventional trial testing a mechanistic hypothesis (inflammation reduction) as surrogate for cancer prevention in an unstudied population; no results reported in registry record.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be inferred from this registration record alone. Results will be needed to determine whether aspirin-induced inflammation reduction correlates with cancer risk reduction in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05557877). This is a study registration, not published results. Lead sponsor: Mayo Clinic. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 60 participants (ESTIMATED). Conditions: Breast Carcinoma. Interventions: PROCEDURE: Biospecimen Collection; DRUG: Low-Dose Aspirin; OTHER: Questionnaire Administration; PROCEDURE: Biopsy. Primary outcome measures: Change in pregnancy-related breast cancer (PRBC) score , Up to 30 days. Brief summary: This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.